Add to ORKGThe era of multiple sclerosis (MS) disease-modifying treatments (DMTs) is less than two decades old, but as the number and usage of DMTs has increased, MS survival has measurably increased and the development of disability has been delayed over time. There are, however, significant cost issues associated with MS treatment.curriculum_fellow; GVSrelationshipsbetweenopticneuritisandmultiplesclerosis; GVSmultiplesclerosisdiagnosis; GVSmultiplesclerosistreatmentstrategies; GVSvisionassessmentinmultiplesclerosi
Abstract Objective The prevailing approaches to selecting multiple sclerosis (MS) disease modifying ...
Objective: To assess whether the introduction of the new diagnostic criteria and disease modifying t...
Multiple sclerosis (MS) is a chronic inflammatory demyelinating neurological disorder with no known ...
Introduction. There are not many conditions in which the last few decades have brought such a major ...
Over the past 18 years, treatments for multiple sclerosis (MS) called disease-modifying therapies (D...
The management of multiple sclerosis (MS) is changing at a rapid rate, with the emergence of a host ...
Multiple sclerosis (MS) is a chronic inflammatory condition of the central nervous system determined...
The emphasis in multiple sclerosis (MS) management has more recently been placed on the development ...
International audienceRR MS evolution has changed since the beginning of the availability of MS dise...
Background Although experts recommend that people with multiple sclerosis (MS) should begin treatmen...
During the 20 past years, the management of multiple sclerosis (MS) has largely changed especially c...
• Multiple sclerosis (MS) is an autoimmune disease of the central nervous system with a multifactori...
The treatment of multiple sclerosis (MS) is becoming more complex, especially with the expanding num...
Prodigious progress in the treatment of multiple sclerosis (MS) has occurred over the last 20 years,...
The first disease modifying therapy for the treatment of MS was approved in 1993. In the 17 years si...
Abstract Objective The prevailing approaches to selecting multiple sclerosis (MS) disease modifying ...
Objective: To assess whether the introduction of the new diagnostic criteria and disease modifying t...
Multiple sclerosis (MS) is a chronic inflammatory demyelinating neurological disorder with no known ...
Introduction. There are not many conditions in which the last few decades have brought such a major ...
Over the past 18 years, treatments for multiple sclerosis (MS) called disease-modifying therapies (D...
The management of multiple sclerosis (MS) is changing at a rapid rate, with the emergence of a host ...
Multiple sclerosis (MS) is a chronic inflammatory condition of the central nervous system determined...
The emphasis in multiple sclerosis (MS) management has more recently been placed on the development ...
International audienceRR MS evolution has changed since the beginning of the availability of MS dise...
Background Although experts recommend that people with multiple sclerosis (MS) should begin treatmen...
During the 20 past years, the management of multiple sclerosis (MS) has largely changed especially c...
• Multiple sclerosis (MS) is an autoimmune disease of the central nervous system with a multifactori...
The treatment of multiple sclerosis (MS) is becoming more complex, especially with the expanding num...
Prodigious progress in the treatment of multiple sclerosis (MS) has occurred over the last 20 years,...
The first disease modifying therapy for the treatment of MS was approved in 1993. In the 17 years si...
Abstract Objective The prevailing approaches to selecting multiple sclerosis (MS) disease modifying ...
Objective: To assess whether the introduction of the new diagnostic criteria and disease modifying t...
Multiple sclerosis (MS) is a chronic inflammatory demyelinating neurological disorder with no known ...